Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. THX Pharma's shares outstanding for the quarter that ended in Dec. 2025 was 13.77 Mil.
THX Pharma's quarterly shares outstanding
increased
from Jun. 2025 (9.57 Mil) to Dec. 2025 (13.77 Mil).
It means THX Pharmaissued new shares from Jun. 2025 to Dec. 2025 .
THX Pharma's annual shares outstanding
increased
from Dec. 2024 (8.85 Mil) to Dec. 2025 (13.77 Mil).
It means THX Pharmaissued new shares from Dec. 2024 to Dec. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
THX Pharma Shares Outstanding (EOP) Related Terms
THX Pharma Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for THX Pharma's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3VG vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, THX Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
THX Pharma Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, THX Pharma's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where THX Pharma's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 13.77 Mil mean?
THX Pharma (STU:3VG) has a Shares Outstanding (EOP) of 13.77 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on THX Pharma and its competitors.
Is THX Pharma's Shares Outstanding (EOP) too high?
THX Pharma's current Shares Outstanding (EOP) is 13.77 Mil. Overall, THX Pharma has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's Shares Outstanding (EOP) compare to VRTX and REGN?
THX Pharma's Shares Outstanding (EOP) of 13.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on THX Pharma and its competitors. THX Pharma's current Shares Outstanding (EOP) is 13.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (STU:3VG) has a current Shares Outstanding (EOP) of 13.77 Mil. The current Shares Outstanding (EOP) is 13.77 Mil. THX Pharma's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For THX Pharma (STU:3VG), the current Shares Outstanding (EOP) is 13.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
31GF Score
Get the complete analysis for STU:3VG
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3VG has been successfully added to your 
